Fabienne Danhier

List of Publications by Year
in descending order

32	8,699	218381 26	414034 32
papers	citations	h-index	g-index

32	32	32	14977
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection. Journal of Controlled Release, 2019, 309, 72-81.	4.8	87
2	Paclitaxel-loaded multifunctional nanoparticles for the targeted treatment of glioblastoma. Journal of Drug Targeting, 2019, 27, 614-623.	2.1	41
3	Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. Journal of Controlled Release, 2018, 281, 42-57.	4.8	147
4	Post-resection treatment of glioblastoma with an injectable nanomedicine-loaded photopolymerizable hydrogel induces long-term survival. International Journal of Pharmaceutics, 2018, 548, 522-529.	2.6	52
5	Magnetic targeting of paclitaxel-loaded poly(lactic-co-glycolic acid)-based nanoparticles for the treatment of glioblastoma. International Journal of Nanomedicine, 2018, Volume 13, 4509-4521.	3.3	73
6	On glioblastoma and the search for a cure: where do we stand?. Cellular and Molecular Life Sciences, 2017, 74, 2451-2466.	2.4	56
7	Novel model of orthotopic U-87 MG glioblastoma resection in athymic nude mice. Journal of Neuroscience Methods, 2017, 284, 96-102.	1.3	33
8	Modeling of the burst release from PLGA micro- and nanoparticles as function of physicochemical parameters and formulation characteristics. International Journal of Pharmaceutics, 2017, 532, 229-240.	2.6	84
9	Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures. Expert Opinion on Drug Delivery, 2017, 14, 851-864.	2.4	261
10	Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma. Journal of Controlled Release, 2015, 210, 95-104.	4.8	89
11	Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors. International Journal of Pharmaceutics, 2015, 479, 399-407.	2.6	56
12	Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation. International Journal of Pharmaceutics, 2015, 481, 154-161.	2.6	82
13	Tumor Targeting by RGD-Grafted PLGA-Based Nanotheranostics Loaded with Paclitaxel and Superparamagnetic Iron Oxides. Methods in Pharmacology and Toxicology, 2015, , 1-17.	0.1	1
14	Iron oxide-loaded nanotheranostics: Major obstacles to in vivo studies and clinical translation. Journal of Controlled Release, 2015, 198, 35-54.	4.8	95
15	Vitamin E-based nanomedicines for anti-cancer drug delivery. Journal of Controlled Release, 2014, 182, 33-44.	4.8	211
16	Self-Assembling Doxorubicinâ€“Tocopherol Succinate Prodrug as a New Drug Delivery System: Synthesis, Characterization, and in Vitro and in Vivo Anticancer Activity. Bioconjugate Chemistry, 2014, 25, 72-81.	1.8	81
17	Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy. Journal of Controlled Release, 2014, 194, 82-91.	4.8	194
18	Vitamin E-based micelles enhance the anticancer activity of doxorubicin. International Journal of Pharmaceutics, 2014, 476, 9-15.	2.6	37

#	Article	IF	Citations
19	Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 252-260.	2.0	20
20	In Vitro Investigations of Smart Drug Delivery Systems Based on Redoxâ€‹scp›S‹/scp›ensitive Crossâ€‹scp›L‹/scp›inked Micelles. Macromolecular Bioscience, 2013, 13, 1661-1670.	2.1	24
21	Potentiation of radiotherapy by a localized antiangiogenic gene therapy. Radiotherapy and Oncology, 2013, 107, 252-258.	0.3	13
22	Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. International Journal of Pharmaceutics, 2013, 447, 94-101.	2.6	196
23	Targeting of Tumor Endothelium by RGD-Grafted PLGA-Nanoparticles. Methods in Enzymology, 2012, 508, 157-175.	0.4	46
24	RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis. Molecular Pharmaceutics, 2012, 9, 2961-2973.	2.3	785
25	PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 2012, 161, 505-522.	4.8	2,692
26	Electron Paramagnetic Resonance Highlights That the Oxygen Effect Contributes to the Radiosensitizing Effect of Paclitaxel. PLoS ONE, 2012, 7, e40772.	1.1	21
27	Fluorescent Labeling of Degradable Poly(Lactide-Co-Glycolide) for Cellular Nanoparticles Tracking in Living Cells. International Journal of Artificial Organs, 2011, 34, 152-160.	0.7	24
28	To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 2010, 148, 135-146.	4.8	2,256
29	Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. International Journal of Pharmaceutics, 2010, 392, 20-28.	2.6	46
30	Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. Journal of Controlled Release, 2009, 133, 11-17.	4.8	526
31	Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. Journal of Controlled Release, 2009, 140, 166-173.	4.8	313
32	Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for Paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 230-238.	2.0	57